Corvia Medical Reports Results from its REDUCE LAP-HF II RCT
A total of 626 patients were randomized at 89 centers across the US, Canada, Europe, Australia, and Japan.
February 1, 2022
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
View the latest clinical trials, studies, data, and updates.
Artivion Announces Publication of On-X® Mitral Heart Valve PROACT Study Results
In tandem with the publication, the study results were presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons on January 30, 2022.
January 31, 2022
TRANSFORM II Randomized Controlled Trial Underway
TRANSFORM II RCT, determined to explore and evaluate the treatment options in native coronary vessels, enrolled the index patient on the 16th December 2021 at Sandro Pertini Hospital, Rome, by the team of Dr. Alessandro Sciahbasi.
January 28, 2022
FX Solutions, SAS. [FX Shoulder, Inc.] Completes Easytech Reversed® Stemless IDE Enrollment in the USA
“This is not only a major milestone for FX, but for the next generation of stemless shoulder arthroplasty and the way we think about reverse total shoulder arthroplasty. As a small company, we are excited and humbled to lead the way and be the first to complete this historic study that may bring a novel device to the U.S. market which has already seen over 2000 implanted in Europe since 2015,” said Baptiste Martin, CEO of FX Shoulder USA.
January 27, 2022
NEJM: New Data on COVID-19 Lung Transplants
The analysis of more than 3,000 lung transplants in the U.S. between Aug. 1, 2020, and Sept. 30, 2021, showed that during the pandemic, 7% of the nation’s lung transplants were performed to treat severe, irreversible lung damage caused by COVID-19. More than half of these patients needed ventilators or extracorporeal membrane oxygenation, or ECMO, before their transplant.
January 26, 2022
Preclinical Study Provides Guidance for Optimizing Safety and Efficacy of Endovascular Hepatic Denervation Devices to Treat Diabetes
“This study leveraged our deep experience in preclinical evaluation of denervation therapies and could not have been performed in a timely manner without the digital morphometry techniques we developed in-house. We remain excited about the potential of neuromodulation technologies and are committed to supporting further innovation in this space,” explained Rami Tzafriri, PhD, lead author and Director of Research and Innovation at CBSET.
January 26, 2022
